Prelude Capital Management’s Usana Health Sciences USNA Stock Holding History

Prelude Capital Management’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-200	Closed	-$15K	–	2026
2020 Q3	$15K	Hold	200	–	–	﹤0.01%	1393
2020 Q2	$15K	Buy	+200	New	+$15.7K	﹤0.01%	1474
2019 Q1	–	Sell	-10,900	Closed	-$1.28M	–	2204
2018 Q4	$1.28M	Buy	10,900 +6,600	+153%	+$763K	0.09%	267
2018 Q3	$518K	Buy	4,300 +3,700	+617%	+$459K	0.03%	518
2018 Q2	$69K	Buy	+600	New	+$65.6K	﹤0.01%	1041

Other funds holding USNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's USNA Position: Q4 2015 in Review

Prelude Capital Management sold out of Usana Health Sciences (USNA) in Q4 2015, closing a stake of 1,632 shares — an estimated $109K sold.

Prelude Capital Management first reported a position in USNA in Q1 2014 and held it in 4 quarters. The position peaked at $123K in Q4 2014. 161 funds tracked by Wall St. Rank hold USNA as of Q4 2015.

Prelude Capital Management reported no remaining Usana Health Sciences position as of Q4 2015 after selling out during the quarter.
Prelude Capital Management sold 1,632 Usana Health Sciences shares in Q4 2015, an estimated $109K.
Prelude Capital Management first reported a position in Usana Health Sciences in Q1 2014 and held it in 4 quarters.
Prelude Capital Management's Usana Health Sciences position peaked at $123K in Q4 2014.
161 funds tracked by Wall St. Rank held Usana Health Sciences as of Q4 2015.

Based on Prelude Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.